Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

UPPI to Offer UltraSPECT’s Advanced NM Imaging Technology for Dose Reduction, Abbreviated Scan Times and Enhanced Resolution

UltraSPECT, a leading provider of nuclear medicine (NM) image reconstruction technology that reduces radiopharmaceutical dose and acquisition time, announces a multi-year distribution agreement with nuclear pharmacy network UPPI LLC for exclusive leasing and/or non-exclusive sale of UltraSPECT’s cardiac and bone imaging applications in the US. 

Ushering molecular imaging into a new age of precision and efficiency, UltraSPECT’s growing product line utilizes the company’s innovative Wide-Beam Reconstruction (WBR™) technology to enhance the performance of gamma cameras and PET scanners.  The technology will cut either standard radiopharmaceutical dose requirements or imaging procedure time in half with no decrease in image quality, while enhancing image resolution. In some cases, exams can be performed in as little as a quarter of the standard procedure time. Additionally, advanced new UltraSPECT applications support a 50 percent reduction in both dose and procedure time. 

See more SPECT Companies

UltraSPECT WBR’s lower dose requirements offer the benefit of minimizing radiation exposure for both patients and technologists, while abbreviated acquisition times reduce the possibility of patient motion artifacts and enhance patient throughput and comfort. Higher image resolution provides greater lesion localization, raising diagnostic confidence and precision.  For many WBR users the result is enhanced equipment utilization, revenues and patient satisfaction and referrals. 

UltraSPECT’s groundbreaking WBR product line is compatible with most major manufacturers’ NM and PET systems as well as all clinical software packages. The technology is a far more cost effective dose reduction alternative to today’s new low-dose SPECT cameras (SPECT Products) with multiple focused detectors.  WBR’s half-dose, half-time and quarter-time capabilities are already successfully utilized in hundreds locations throughout the U.S. and Europe.

 "UPPI has been searching for different ways to stretch the limited technetium supplies during shortages and extend the solutions provided by our independently owned radiopharmacies to their Nuclear Medicine customers.  Our partnership with UltraSPECT will allow our members to lease a cost effective solution to their customers, enabling them to achieve improved patient safety, higher efficiency, and maintain steady patient throughput during radiopharmaceutical shortages with the optimum image quality." said Perry Polsinelli, President and CEO of UPPI LLC.

Source: UltraSPECT